Haisco Pharmaceutical Group Co.,Ltd. (002653.SZ) Receives Clinical Trial Approval for New Indication of Innovative Drug HSK47388 Tablets

Stock News

Sep 03

Haisco Pharmaceutical Group Co.,Ltd. (002653.SZ) announced that the company recently received a "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. Following review, the HSK47388 tablets application submitted in June 2025 meets the relevant requirements for drug registration, and approval has been granted for clinical trials of this product.

HSK47388 tablets are an oral, potent, and highly selective drug independently developed by the company, intended for the treatment of autoimmune diseases. Preclinical study results demonstrate that HSK47388 exhibits significant dose-dependent efficacy in rat colitis models, while also showing good tolerability and a large safety window, making it a drug with substantial development potential.

This application represents another new indication clinical trial application for HSK47388 tablets in the field of autoimmune diseases, and is expected to provide a new treatment option for patients with autoimmune diseases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1100177082"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100177082\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100177082?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-03 15:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100177082","market":"fut","top_or_hot":-1,"title":"Haisco Pharmaceutical Group Co.,Ltd. (002653.SZ) Receives Clinical Trial Approval for New Indication of Innovative Drug HSK47388 Tablets","media":"Stock News","content":"<p>Haisco Pharmaceutical Group Co.,Ltd. (002653.SZ) announced that the company recently received a \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration. Following review, the HSK47388 tablets application submitted in June 2025 meets the relevant requirements for drug registration, and approval has been granted for clinical trials of this product.</p>\n<p>HSK47388 tablets are an oral, potent, and highly selective drug independently developed by the company, intended for the treatment of autoimmune diseases. Preclinical study results demonstrate that HSK47388 exhibits significant dose-dependent efficacy in rat colitis models, while also showing good tolerability and a large safety window, making it a drug with substantial development potential.</p>\n<p>This application represents another new indication clinical trial application for HSK47388 tablets in the field of autoimmune diseases, and is expected to provide a new treatment option for patients with autoimmune diseases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Haisco Pharmaceutical Group Co.,Ltd. (002653.SZ) Receives Clinical Trial Approval for New Indication of Innovative Drug HSK47388 Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHaisco Pharmaceutical Group Co.,Ltd. (002653.SZ) Receives Clinical Trial Approval for New Indication of Innovative Drug HSK47388 Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-03 15:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Haisco Pharmaceutical Group Co.,Ltd. (002653.SZ) announced that the company recently received a \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration. Following review, the HSK47388 tablets application submitted in June 2025 meets the relevant requirements for drug registration, and approval has been granted for clinical trials of this product.</p>\n<p>HSK47388 tablets are an oral, potent, and highly selective drug independently developed by the company, intended for the treatment of autoimmune diseases. Preclinical study results demonstrate that HSK47388 exhibits significant dose-dependent efficacy in rat colitis models, while also showing good tolerability and a large safety window, making it a drug with substantial development potential.</p>\n<p>This application represents another new indication clinical trial application for HSK47388 tablets in the field of autoimmune diseases, and is expected to provide a new treatment option for patients with autoimmune diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1100177082","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100177082","pubTimestamp":1756886304,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Haisco Pharmaceutical Group Co.,Ltd. (002653.SZ) announced that the company recently received a \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration. Following...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"海思科药业集团股份有限公司。（002653.SZ）创新药HSK47388片新适应症获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"002653":1,"06978":1},"content_text":"Haisco Pharmaceutical Group Co.,Ltd. (002653.SZ) announced that the company recently received a \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration. Following review, the HSK47388 tablets application submitted in June 2025 meets the relevant requirements for drug registration, and approval has been granted for clinical trials of this product.\nHSK47388 tablets are an oral, potent, and highly selective drug independently developed by the company, intended for the treatment of autoimmune diseases. Preclinical study results demonstrate that HSK47388 exhibits significant dose-dependent efficacy in rat colitis models, while also showing good tolerability and a large safety window, making it a drug with substantial development potential.\nThis application represents another new indication clinical trial application for HSK47388 tablets in the field of autoimmune diseases, and is expected to provide a new treatment option for patients with autoimmune diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}